Your search relates to more than one category
Medical News Today (Free subscription) | yesterday
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
Rocky Mount Telegram - Business (Free subscription) | 11/25/2009
NEW YORK — Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of it...
Miami Herald (Free subscription) | 11/25/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
San Diego Union (Free subscription) | 11/25/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
Seattle Post-Intelligencer (Free subscription) | 11/25/2009
NEW YORK -- Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
Seattle Times (Free subscription) | 11/25/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
San Fransisco Chronicle (Free subscription) | 11/25/2009
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin. The Rockville, Md., company did not say when it expected a response to its biologics license application, which was submitted to the Food and Drug... Human Genome Sciences - Hepatitis C - Biology - Genetics - Eukaryotic
SeekingAlpha.com (Free subscription) | 11/25/2009
Zacks.com submits: Recently, Human Genome Sciences, Inc. ( HGSI ) and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead inhibitor-of-apoptosis protein (IAP), HGS1029, as monotherapy in patients with advanced lymphoid tumors. An additional phase I clinical trial of the compound is being conducted to evaluate...
The Washington Business Journal (Free subscription) | 11/25/2009
Human Genome Sciences Inc. announced today it’s submitted its second application so far this year to federal regulators to sell a drug on the market, this most recent being for its hepatitis C treatment called Zalbin. (HGSI)
Business Wire (Free subscription) | 11/25/2009
ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon...
Medical News Today (Free subscription) | 11/24/2009
Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
Business Wire (Free subscription) | 11/23/2009
ROCKVILLE, Md. & MONTREAL--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. “We are pleased to initiate this first human...
Stock Market Analysis (Free subscription) | 11/28/2009
Below is the list of the Top Stock Gainers so far in 2009. As a screener, only stocks with at least 50,000 in volume and over $2 per share price are included. Topping the list going into December is Diedrich Coffee Inc. (DDRX). You can find my previous report - Right Here Discuss Stocks - http://stockstobuy.org Top Stocks as of December 2009 #1. Netlist Inc. ( NLST ) - $6.25 Up 2055%...
